233 related articles for article (PubMed ID: 20177391)
1. Principal component analysis of dynamic contrast enhanced MRI in human prostate cancer.
Eyal E; Bloch BN; Rofsky NM; Furman-Haran E; Genega EM; Lenkinski RE; Degani H
Invest Radiol; 2010 Apr; 45(4):174-81. PubMed ID: 20177391
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
[TBL] [Abstract][Full Text] [Related]
3. Principal component analysis of breast DCE-MRI adjusted with a model-based method.
Eyal E; Badikhi D; Furman-Haran E; Kelcz F; Kirshenbaum KJ; Degani H
J Magn Reson Imaging; 2009 Nov; 30(5):989-98. PubMed ID: 19856419
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence.
Franiel T; Lüdemann L; Rudolph B; Rehbein H; Staack A; Taupitz M; Prochnow D; Beyersdorff D
Invest Radiol; 2008 Jul; 43(7):481-7. PubMed ID: 18580330
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer detection on dynamic contrast-enhanced MRI: computer-aided diagnosis versus single perfusion parameter maps.
Sung YS; Kwon HJ; Park BW; Cho G; Lee CK; Cho KS; Kim JK
AJR Am J Roentgenol; 2011 Nov; 197(5):1122-9. PubMed ID: 22021504
[TBL] [Abstract][Full Text] [Related]
6. [Quantitative dynamic MRI and localisation of non-palpable prostate cancer].
Cornud F; Beuvon F; Thévenin F; Chauveinc L; Vieillefond A; Descazeaux A; Flam T
Prog Urol; 2009 Jun; 19(6):401-13. PubMed ID: 19467459
[TBL] [Abstract][Full Text] [Related]
7. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
Ocak I; Bernardo M; Metzger G; Barrett T; Pinto P; Albert PS; Choyke PL
AJR Am J Roentgenol; 2007 Oct; 189(4):849. PubMed ID: 17885055
[TBL] [Abstract][Full Text] [Related]
8. Analysis of prostate DCE-MRI: comparison of fast exchange limit and fast exchange regimen pharmacokinetic models in the discrimination of malignant from normal tissue.
Lowry M; Zelhof B; Liney GP; Gibbs P; Pickles MD; Turnbull LW
Invest Radiol; 2009 Sep; 44(9):577-84. PubMed ID: 19668002
[TBL] [Abstract][Full Text] [Related]
9. Dynamic contrast-enhanced MR imaging features of the normal central zone of the prostate.
Hansford BG; Karademir I; Peng Y; Jiang Y; Karczmar G; Thomas S; Yousuf A; Antic T; Eggener S; Oto A
Acad Radiol; 2014 May; 21(5):569-77. PubMed ID: 24703469
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of semi-quantitative dynamic contrast-enhanced MRI parameters for prostate cancer in correlation to whole-mount histopathology.
Isebaert S; De Keyzer F; Haustermans K; Lerut E; Roskams T; Roebben I; Van Poppel H; Joniau S; Oyen R
Eur J Radiol; 2012 Mar; 81(3):e217-22. PubMed ID: 21349667
[TBL] [Abstract][Full Text] [Related]
11. Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization.
Kim JK; Hong SS; Choi YJ; Park SH; Ahn H; Kim CS; Cho KS
J Magn Reson Imaging; 2005 Nov; 22(5):639-46. PubMed ID: 16200542
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetic MRI of the prostate: parameters for differentiating low-grade and high-grade prostate cancer].
Franiel T; Lüdemann L; Taupitz M; Rost J; Asbach P; Beyersdorff D
Rofo; 2009 Jun; 181(6):536-42. PubMed ID: 19353483
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging.
Kitajima K; Kaji Y; Fukabori Y; Yoshida K; Suganuma N; Sugimura K
J Magn Reson Imaging; 2010 Mar; 31(3):625-31. PubMed ID: 20187206
[TBL] [Abstract][Full Text] [Related]
14. Description of magnetic resonance imaging-derived enhancement variables in pathologically confirmed prostate cancer and normal peripheral zone regions.
Zelhof B; Lowry M; Rodrigues G; Kraus S; Turnbull L
BJU Int; 2009 Sep; 104(5):621-7. PubMed ID: 19281464
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of prostate cancer from normal prostate tissue in an animal model: conventional MRI and dynamic contrast-enhanced MRI.
Gemeinhardt O; Lüdemann L; Prochnow D; Abramjuk C; Taupitz M; Hamm B; Beyersdorff D
Rofo; 2005 Jul; 177(7):935-9. PubMed ID: 15973594
[TBL] [Abstract][Full Text] [Related]
16. Benign prostatic hyperplasia: evaluation of T1, T2, and microvascular characteristics with T1-weighted dynamic contrast-enhanced MRI.
Kershaw LE; Hutchinson CE; Buckley DL
J Magn Reson Imaging; 2009 Mar; 29(3):641-8. PubMed ID: 19243046
[TBL] [Abstract][Full Text] [Related]
17. Dynamic contrast enhanced MRI of the prostate: comparison of gadobutrol and Gd-DTPA.
Durmus T; Vollnberg B; Schwenke C; Kilic E; Huppertz A; Taupitz M; Franiel T
Rofo; 2013 Sep; 185(9):862-8. PubMed ID: 23888476
[TBL] [Abstract][Full Text] [Related]
18. Reproducibility of the aortic input function (AIF) derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the kidneys in a volunteer study.
Mendichovszky IA; Cutajar M; Gordon I
Eur J Radiol; 2009 Sep; 71(3):576-81. PubMed ID: 19004588
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging.
Tanimoto A; Nakashima J; Kohno H; Shinmoto H; Kuribayashi S
J Magn Reson Imaging; 2007 Jan; 25(1):146-52. PubMed ID: 17139633
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined.
Chen M; Dang HD; Wang JY; Zhou C; Li SY; Wang WC; Zhao WF; Yang ZH; Zhong CY; Li GZ
Acta Radiol; 2008 Jun; 49(5):602-10. PubMed ID: 18568549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
